Xenetic Biosciences, Inc. has announced an expansion of its research and development collaboration with The Scripps Research Institute to advance its DNase platform. This collaboration will now include additional models of lymphoma and leukemia in order to further validate the promising DNase-I data observed to date. Xenetic's DNase-based oncology platform targets neutrophil extracellular traps (NETs), which are implicated in cancer spread and immunosuppression. Preclinical studies have shown that co-administration of DNase I with CAR-T cell therapy significantly improves therapeutic outcomes in models of lymphoma and metastatic melanoma. This has prompted the expansion of the research program to include further models to validate these findings. The company is moving towards Phase 1 clinical development for treating pancreatic carcinoma and other solid tumors with its systemic DNase I candidate, XBIO-015, though no specific results from these trials have been presented yet.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.